Home › Funds › GW&K Investment Management, LLC › HALO

GW&K Investment Management, LLC position in HALO

HALOZYME THERAPEUTICS INC · Health Care

GW&K Investment Management, LLC reported holding 1,140,057 shares of HALO (HALOZYME THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$125.9M, representing 1.07% of its reported portfolio and ranking #5 among its reported holdings. GW&K Investment Management, LLC has disclosed HALO holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)1.14M sh
Reported value held$125.86M
Portfolio Weight1.07%
First reportedQ3 2023
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How GW&K Investment Management, LLC's HALO position evolved

GW&K Investment Management, LLC first disclosed a stake in HALO in Q3 2023 at 2,344,305 shares (US$89.6M). The position peaked in Q3 2026 at 1,140,057 shares, worth US$125.9M. Across 13 filings, GW&K Investment Management, LLC increased the stake 1 time(s), trimmed it 11 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 1,140,057 shares valued at US$125.9M — a reduction of -213,826 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q3 2023 2.34M $89.55M New
Q4 2023 2.23M $82.29M Reduce
Q1 2024 2.20M $89.37M Reduce
Q2 2024 2.18M $114.14M Reduce
Q3 2024 1.76M $100.87M Reduce
Q4 2024 1.75M $83.46M Reduce
Q1 2025 1.46M $93.47M Reduce
Q2 2025 1.42M $74.10M Reduce
Q3 2025 1.26M $92.53M Reduce
Q4 2025 1.25M $84.44M Reduce
Q1 2026 1.39M $90.09M Add
Q2 2026 1.35M $105.97M Reduce
Q3 2026 1.14M $125.86M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About HALO and 13F data

HALO (HALOZYME THERAPEUTICS INC) is a Health Care company. 44 other funds we track also report a position in HALO — the largest reported positions include CONGRESS ASSET MANAGEMENT CO (US$251.9M), SNYDER CAPITAL MANAGEMENT L P (US$187.5M), WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC (US$178.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding HALO

All HALO fund holders →

FAQ

How long has GW&K Investment Management, LLC held HALO?

GW&K Investment Management, LLC has disclosed HALO holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is GW&K Investment Management, LLC's current position in HALO?

As of Q3 2026, GW&K Investment Management, LLC holds 1.14M shares of HALO (HALOZYME THERAPEUTICS INC), valued at $125.86M, representing 1.07% of its reported portfolio and ranking #5.

Has GW&K Investment Management, LLC been buying or selling HALO?

In the latest 13F filing (Q3 2026), GW&K Investment Management, LLC reduced its position in HALO. The position peaked in Q3 2026 at 1.14M shares.

Which other funds hold HALO?

Other major institutional holders of HALO include CONGRESS ASSET MANAGEMENT CO, SNYDER CAPITAL MANAGEMENT L P, WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC, among 44 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.